Specialty Finance

Wise PLC Class A

Jefferies Maintains Wise PLC A Class Shares Buy Rating, Target Price at 1231 Pounds

UBS Analyst Maintains Buy Rating on Wise PLC A Shares

Wise Considers Entering the Cryptocurrency Market

WISE Secures Final Approval for e-Payment Services from UAE Central Bank

German savings banks partner with BNY Mellon to lower international transfer fees

Goodman analyzes tech industry stocks and gives buy ratings

Payment Firm Wise Plc Seeks US Oversight and Plans to Relocate Listing to US

Peter Thiel-related Investors Sell $70 Million Worth of Wise Shares

WISE plans to move its primary listing from London to the US

HKUD

01024

UBS analyst maintained a Buy rating on Kuaishou Technology Class B yesterday and set a price target of HK$68.00.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks In a report released yesterday, DBS also maintained a Buy rating on the stock with a HK$67.00 price target.

- UBS analyst confirmed a Buy rating on Kuaishou Technology Class B with a price target of HK$68.00.  
- Similarly, DBS maintained a Buy rating with a price target of HK$67.00 in a report released on the same day.  
- Both analyses reflect confidence in the stock's performance and potential in the market.

Tip Ranks

Kuaishou HK SDR 5to1

KUAISHOU-W

UBS Group AG

DBS Group

KUAISHOU-WR

Kuaishou Technology Class B (1024) Receives a Buy from UBS

WISE

Goldman Sachs analyst Mohammed Moawalla has reiterated a Buy rating on Wise stock, citing the company's shift to a U.S. listing and adoption of U.S. GAAP as non-disruptive to its fundamentals. He maintains a price target of 1,400p for the UK listing and introduces a $19 target for the U.S. listing, reflecting confidence in Wise's growth prospects. Moawalla's analysis suggests that the operational outlook remains strong despite the changes, indicating potential upside for investors.

- Goldman Sachs analyst Mohammed Moawalla maintained a bullish stance on WISE stock and assigned a "buy" rating.  
- He underscores that Wise's transition of its main listing to the U.S. and adoption of U.S. GAAP does not alter his fundamental outlook, maintaining target prices of 1,400 pence for the UK and $19 for the U.S. listing.  
- Moawalla believes that Wise's operational performance and growth outlook justify the potential for upward movement at current levels.

Goldman Sachs

Adyen N.V.

GS Hldg R

Analyst Reiterates Buy on Wise as U.S. Listing and GAAP Shift Leave Fundamentals Intact; Price Targets Set at 1,400p and $19

Wise executives presented their growth strategy post-Nasdaq listing, focusing on cross-border payments and expanding product offerings. CEO Kristo Käärmann highlighted customer savings of £3.3 billion in fees and rapid transaction speeds, with 75% arriving in under 20 seconds. The company aims to enhance its Wise Account and business tools, targeting larger businesses. Wise's infrastructure, with over 80 global licenses, is a competitive advantage. The Wise Platform, its fastest-growing product, allows banks to offer international payments. CFO Emmanuel Thomassin reported consistent profitability and projected 2026 revenue of $2.5 billion.

Market Beat

NU Holdings

LiveRamp

Standard Chartered PLC

STANCHART

Itau Unibanco Banco Mult

Morgan Stanley

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Wise Lays Out Post-Nasdaq Growth Plan, Targets Banks With Payments Platform

Wise Group shares are trading lower amid volatility following its Nasdaq listing.

benzinga_article

Nasdaq

UK fintech Wise has made its US trading debut with a Nasdaq listing under the ticker WSE, alongside a secondary listing on the London Stock Exchange. CEO Kristo Kaarmann aims to increase liquidity and expand the company's presence in the US market. Wise reported a 19% rise in net revenue to $2.5 billion for the year ending March 31, with customer holdings reaching $39 billion. The dual listing allows Wise to maintain its dual-class share structure, which provides Kaarmann with voting control. Wise is also pursuing growth through its Wise Platform business and has applied to form a US national trust bank.

Businesstimes News

S&P 500

UK fintech Wise makes US trading debut with dual listing

Plans to move Wise stock market listing to US approved by High Court judge - In July last year, Wise’s co-founder, Taavet Hinrikus, described the firm’s plans as ‘inappropriate and unfair’.

Plans to move Wise stock market listing to US approved by High Court judge

Wise PLC has granted a long-term incentive award of 90,396 Class A ordinary shares to Diana Avila Gonzalez, its Global Head of Banking and Expansion. The award, reflecting the company's strategy to retain senior leadership, will vest quarterly over four years starting July 15, 2026. This move underscores Wise's commitment to executive retention as it competes in the international payments sector. Analysts rate WISE stock as a Buy with a price target of £1260.00, highlighting strong financial performance despite a high valuation.

Wise Grants Long-Term Share Award to Global Banking Chief

Wise and Revolut, two London fintechs, view U.S. stock listings as crucial for their expansion into the U.S. market. Wise plans to switch its primary listing to the U.S. by 2025, while Revolut aims for a U.S. or dual listing by 2028, seeking a U.S. banking license to enhance its operations. Both companies are focusing on product development and optimizing customer experience in the U.S. market, attracted by its liquidity and growth potential. Wise also plans to support digital assets, while Revolut is expanding its services to U.S. consumers.

American Banker

Why U.S. listings are vital to Wise and Revolut

Recursion Pharmaceuticals (RXRX) $Recursion Pharmaceuticals(RXRX.US) In-depth Research Report: From Phenotypic Screening to Vertical Integration—Revaluation After Exscientia Acquisition and the New Paradigm of AI Drug Development 1. Core Investment Thesis and Summary Recursion Pharmaceuticals $Recursion Pharmaceuticals(RXRX.US) is at the most critical turning point in its corporate life cycle...

Recursion Pharmaceuticals

Takeda Pharmaceutical Co. Ltd.

XTALPI

BetaShares Holdings Pty Ltd.

Bright Minds Biosciences

Standard BioTools

Genetic Technologies Limited

Ameriprise Financial

Schw Interm Us Trsy

Sensata Tech

RXRX 深度分析， By Gemini Deepresearch

$iShares Bitcoin Trust ETF(IBIT.US)The relationship between JPMorgan and Bitcoin/cryptocurrency is essentially Wall Street's classic 'talk the talk but walk the walk' script, and by 2025, this drama has reached its climax. I (actually Grok. 😂) went through all the news on X.com and mainstream media recently (throughout 2025, especially Q3-Q4), and after peeling back the layers...

Wise PLC Class A(WISE.UK)

Kuaishou Technology Class B (1024) Receives a Buy from UBS

Analyst Reiterates Buy on Wise as U.S. Listing and GAAP Shift Leave Fundamentals Intact; Price Targets Set at 1,400p and $19

Wise Lays Out Post-Nasdaq Growth Plan, Targets Banks With Payments Platform

Wise Group shares are trading lower amid volatility following its Nasdaq listing.

UK fintech Wise makes US trading debut with dual listing